Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants

Phase 1

Completed

Conditions: Osteoarthritis
Knee

Interventions: Drug: LNA043
Drug: Placebo

First Posted Date: 2020-09-25

Last Posted Date: 2022-08-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT04564053

Locations: 🇯🇵
Novartis Investigative Site, Osaka, Japan

MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Conditions: Acute Lymphoblastic Leukemia (ALL)

First Posted Date: 2020-09-23

Last Posted Date: 2022-08-09

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04559555

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Phase 3

Completed

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions: Drug: LNP023
Drug: Eculizumab
Drug: Ravulizumab

First Posted Date: 2020-09-22

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 97

Registration Number: NCT04558918

Locations: 🇺🇸
City Of Hope National Med Center City of Hope Medical Center, Duarte, California, United States
🇺🇸
Augusta University Georgia Patient Treatment, Augusta, Georgia, United States
🇺🇸
Univ Cali Irvine ALS Neuromuscular, Orange, California, United States

and more 3 locations

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Phase 3

Recruiting

Conditions: Primary IgA Nephropathy

Interventions: Drug: LNP023

First Posted Date: 2020-09-21

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 500

Registration Number: NCT04557462

Locations: 🇺🇸
AZ Kidney Dise and Hypertension Ctr, Glendale, Arizona, United States
🇺🇸
Kaiser Permanente, San Diego, California, United States
🇺🇸
North America Research Institute, San Dimas, California, United States

and more 8 locations

Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria

Phase 2

Recruiting

Conditions: Uncomplicated Plasmodium Falciparum Malaria

Interventions: Drug: KAF156
Drug: Coartem
Drug: LUM-SDF

First Posted Date: 2020-09-14

Last Posted Date: 2024-07-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 295

Registration Number: NCT04546633

Locations: 🇲🇱
Novartis Investigative Site, Sotuba, Mali

Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

Completed

Conditions: Malignant Melanoma

Interventions: Drug: dabrafenib + trametinib

First Posted Date: 2020-09-14

Last Posted Date: 2023-05-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3

Registration Number: NCT04547946

Locations: 🇵🇹
Novartis Investigative Site, Oporto, North, Portugal

Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

Active, not recruiting

Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Diabetic Macular Edema (DME)

Interventions: Drug: brolucizumab

First Posted Date: 2020-09-10

Last Posted Date: 2024-08-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 573

Registration Number: NCT04543331

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

Conditions: Melanoma
Adjuvant

First Posted Date: 2020-09-10

Last Posted Date: 2024-11-11

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04544202

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Neoplasms

Interventions: Drug: Alpelisib
Drug: Placebo
Drug: Fulvestrant

First Posted Date: 2020-09-10

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 69

Registration Number: NCT04544189

Locations: 🇨🇳
Novartis Investigative Site, Tianjin, China

Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome

Phase 2

Active, not recruiting

Conditions: Sjogren's Syndrome

Interventions: Drug: CFZ533 (iscalimab)
Other: CFZ533 Placebo

First Posted Date: 2020-09-09

Last Posted Date: 2024-08-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 206

Registration Number: NCT04541589

Locations: 🇺🇸
Tufts School of Dental Medicine, Boston, Massachusetts, United States
🇺🇸
The John Hopkins Jerome L Greene Sjogren, Baltimore, Maryland, United States
🇺🇸
Ochsner Health System Research Department, Baton Rouge, Louisiana, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy